# Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

> **NCT04098653** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 196 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation
- Conditioning
- Myeloid Tumors

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Busulfan (BU)
- **DRUG:** Cyclophosphamide (CY)

## Key facts

- **NCT ID:** NCT04098653
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09
- **Primary completion:** 2022-08
- **Final completion:** 2023-08
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2019-09-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04098653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04098653, "Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04098653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*